Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance

被引:8
|
作者
Siopi, Maria [1 ,2 ]
Pachoulis, Ioannis [1 ,2 ]
Leventaki, Sevasti [1 ,2 ]
Spruijtenburg, Bram [3 ,4 ]
Meis, Jacques F. [4 ,5 ]
Pournaras, Spyros [1 ]
Vrioni, Georgia [6 ]
Tsakris, Athanasios [6 ]
Meletiadis, Joseph [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Med Sch, Clin Microbiol Lab, Athens, Greece
[2] Univ West Attica, Dept Biomed Sci, Mol Microbiol & Immunol Lab, Athens, Greece
[3] Canisius Wilhelmina Hosp CWZ Dicoon, Nijmegen, Netherlands
[4] Radboudumc CWZ Ctr Expertise Mycol, Nijmegen, Netherlands
[5] Univ Cologne, Inst Translat Res, Excellence Ctr Med Mycol ECMM, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany
[6] Natl & Kapodistrian Univ Athens, Med Sch, Dept Microbiol, Athens, Greece
关键词
Candida auris; Vitek; 2; wild-type upper limit value; antifungal susceptibility testing; resistance; BROTH MICRODILUTION; CLSI; VARIABILITY; HAEMULONII; ETEST;
D O I
10.1128/jcm.01528-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Although the Vitek 2 system is broadly used for antifungal susceptibility testing of Candida spp., its performance against Candida auris has been assessed using limited number of isolates recovered from restricted geographic areas. We therefore compared Vitek 2 system with the reference Clinical and Laboratory Standards Institute (CLSI) broth microdilution method using an international collection of 100 C. auris isolates belonging to different clades. The agreement +/- 1 twofold dilution between the two methods and the categorical agreement (CA) based on the Centers for Disease Control and Prevention's (CDC's) tentative resistance breakpoints and Vitek 2-specific wild-type upper limit values (WT-ULVs) were determined. The CLSI-Vitek 2 agreement was poor for 5-flucytosine (0%), fluconazole (16%), and amphotericin B (29%), and moderate for voriconazole (61%), micafungin (67%), and caspofungin (81%). Significant interpretation errors were recorded using the CDC breakpoints for amphotericin B (31% CA, 69% major errors; MaEs) and fluconazole (69% CA, 31% very major errors; VmEs), but not for echinocandins (99% CA, 1% MaEs for both micafungin and caspofungin) for which the Vitek 2 allowed correct categorization of echinocandin-resistant FKS1 mutant isolates. Discrepancies were reduced when the Vitek 2 WT-ULV of 16 mg/L for amphotericin B (98% CA, 2% MaEs) and of 4 mg/L for fluconazole (96% CA, 1% MaEs, 3% VmEs) were used. In conclusion, the Vitek 2 system performed well for echinocandin susceptibility testing of C .auris. Resistance to fluconazole was underestimated whereas resistance to amphotericin B was overestimated using the CDC breakpoints of >= 32 and >= 2 mg/L, respectively. Vitek 2 minimun inhibitory concentrations (MICs) >4 mg/L indicated resistance to fluconazole and Vitek 2 MICs <= 16 mg/L indicated non-resistance to amphotericin B.
引用
收藏
页数:14
相关论文
共 38 条
  • [31] Comparative Analysis of the Vitek 2 Antifungal Susceptibility System and E-test with the CLSI M27-A3 Broth Microdilution Method for Susceptibility Testing of Indian Clinical Isolates of Cryptococcus neoformans
    Tewari, Aarti
    Behera, Bijayani
    Mathur, Purva
    Xess, Immaculata
    MYCOPATHOLOGIA, 2012, 173 (5-6) : 427 - 433
  • [32] Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole-susceptible clinical Candida isolates
    Heep, M.
    Grover, P.
    Brown, N. P.
    Sahm, D.
    Jones, M. E.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S474 - S475
  • [33] Evaluation of RT-PCR method to identification of fluconazole resistance genes, ERG11 and CDR2, in native clinical Candida albicans isolates from AIDS patients
    Yadegari, M.
    Yadegari, M.
    Farahbakhsh, E.
    Bazl, M. R.
    Armaki, M. T.
    Katiraee, F.
    MYCOSES, 2011, 54 : 133 - 134
  • [34] In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.:: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods
    Pfaller, MA
    Messer, SA
    Boyken, L
    Huynh, H
    Hollis, RJ
    Diekema, DJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) : 3518 - 3521
  • [35] Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the national committee for clinical laboratory standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans
    RodriguezTudela, JL
    Berenguer, J
    MartinezSuarez, JV
    Sanchez, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) : 1998 - 2003
  • [36] Performance of the EUCAST Disk Diffusion Method, the CLSI Agar Screen Method, and the Vitek 2 Automated Antimicrobial Susceptibility Testing System for Detection of Clinical Isolates of Enterococci with Low- and Medium-Level VanB-Type Vancomycin Resistance: a Multicenter Study
    Hegstad, Kristin
    Giske, Christian G.
    Haldorsen, Bjorg
    Matuschek, Erika
    Schonning, Kristian
    Leegaard, Truls M.
    Kahlmeter, Gunnar
    Sundsfjord, Arnfinn
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (05) : 1582 - 1589
  • [37] Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida Species
    Astvad, Karen M.
    Perlin, David S.
    Johansen, Helle K.
    Jensen, Rasmus H.
    Arendrup, Maiken C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) : 177 - 182
  • [38] Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
    Melhem, Marcia S. C.
    Coelho, Vivian C.
    Fonseca, Claudia A.
    de Oliveira, Lidiane
    Bonfietti, Lucas X.
    Szeszs, Maria W.
    Magri, Marcello M. C.
    Dorneles, Francine S.
    Taguchi, Hideaki
    Moreira, Daniel V. S.
    Motta, Adriana L.
    Batista, Marjorie, V
    Kamei, Katsuhiko
    Shikanai-Yasuda, Maria A.
    PHARMACEUTICS, 2022, 14 (10)